Cooper Companies (The) (COO) Q2 2025 10-Q Quarterly Report

Filed: May 30, 2025Period ending Apr 30, 2025
Health Care
Ophthalmic GoodsSEC EDGAR

Cooper Companies (The) (COO) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on May 30, 2025 for the fiscal period ending Apr 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

Cooper Companies (The) Q2 2025 10-Q Analysis

Risk Factors

  • No newly added risk factors disclosed in this quarter's 10-Q versus prior 10-K
  • Most materially updated risk: increased focus on silicone hydrogel and single-use contact lenses due to market shift and growth in preferred modalities
+3 more insights

Cooper Companies (The) Q2 2025 Quarterly Financials
XBRL

Revenue

$1.0B

+6.3% YoY +3.9% QoQ

Net Income

$88M

-1.3% YoY -15.9% QoQ

Gross Margin

67.8%

+79bp YoY -68bp QoQ

Operating Margin

18.4%

+128bp YoY -43bp QoQ

Net Margin

8.7%

-68bp YoY -206bp QoQ

EPS (Diluted)

$0.44

0.0% YoY -15.4% QoQ

Operating Cash Flow

$96M

-13.3% YoY -49.5% QoQ

Source: XBRL data from Cooper Companies (The) Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Cooper Companies (The) Quarterly Reports

Get deeper insights on Cooper Companies (The)

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.